How much can be gained by more systematic prevention of stroke?

International Journal of Stroke

Volumn 3, Issue 4, 2008, Pages 266-271

  Goldstein, Larry B ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Compliance; Health services; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ANTICOAGULATION; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DRUG EFFICACY; ENDARTERECTOMY; EXERCISE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MEDLINE; MONOTHERAPY; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 52249087784     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2008.00226.x     Document Type: Review

References (52)

1. EUSI Executive Committee and EUSI Writing Committee: European Stroke Initiative: Ischaemic Stroke - Prophylaxis and Treatment. Heidelberg, Germany: EUSI Executive Committee and EUSI Writing Committee, 2003.
2. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-633.
3. Norris JW, Perry JR, Djan P: Stroke prevention by screening for asymptomatic carotid stenosis: Validation of evidence-based guidelines. Neurology 1996; 46(Suppl):A325.
4. Hayden M, Pigone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US preventive services task force. Ann Intern Med 2002; 136:161-72.
5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 483S-512S.
6. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37:577-617.
7. Swedenborg J, Malm J, Rothwell PM, Wahlgren NG. Karolinska Stroke Update. Consensus statements. 2. Carotid Endarterectomy. Stockholm, Sweden; 2004 Contract No: Document Number.
8. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke. Stroke 2007; 38:1655-711.
9. Pearson TA, Bazzarre T, Daniels SR et al. AHA guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association expert panel on population and prevention science. Circulation 2003; 107:645-51.
10. American Heart Association: Heart disease and stroke statistics - 2008 update. Dallas, Texas, American Heart Association, 2008: 15.
11. Whisnant JP: Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke 1997; 28:1840-4.
12. Samsa GP, Cohen SJ, Goldstein LB et al. Knowledge of risk among patients at increased risk for stroke. Stroke 1997; 28:916-21.
13. Kothari R, Sauerbeck L, Jauch E et al. Patients' awareness of stroke signs, symptoms, and risk factors. Stroke 1997; 28:1871-5.
14. Pancioli AM, Broderick J, Kothari R et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998; 279:1288-92.
15. Sug Yoon S, Heller RF, Levi C, Wiggers J, Fitzgerald PE: Knowledge of stroke risk factors, warning symptoms, and treatment among an Australian urban population. Stroke 2001; 32:1926-30.
16. Parahoo K, Thompson K, Cooper M, Stringer M, Ennis E, McCollam P: Stroke: Awareness of the signs, symptoms and risk factors - a population-based survey. Cerebrovas Dis 2003; 16:134-40.
17. Schneider AT, Pancioli AM, Khoury JC et al. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA 2003; 289:343-6.
18. Silver FL, Rubini F, Black D, Hodgson CS: Advertising strategies to increase public knowledge of the warning signs of stroke. Stroke 2003; 34:1965-9.
19. Ruland S, Raman R, Chaturvedi S, Leurgans S, Gorelick PB: Awareness, treatment, and control of vascular risk factors in African Americans with stroke. Neurology 2003; 60:64-8.
20. Nedeltchev K, Fischer U, Arnold M, Kappeler L, Mattle HP: Low awareness of transient ischemic attacks and risk factors of stroke in a Swiss urban community. J Neurol 2007; 254:179-84.
21. DeLemos CD, Atkinson RP, Croopnick SL, Wentworth DA, Akins PT: How effective are 'community' stroke screening programs at improving stroke knowledge and prevention practices? Results of a 3-month follow-up study. Stroke 2003; 34:E247-9.
22. Sacco RL: The 2006 William FeSnberg lecture: shifting the paradigm from stroke to global vascular risk estimation. Stroke 2007; 38:1980-7.
23. Howard G, Safford MM, Meschia JF et al. Stroke symptoms in individuals reporting no prior stroke or transient ischemic attack are associated with a decrease in indices of mental and physical functioning. Stroke 2007; 38:2446-52.
24. Wadley VG, McClure LA, Howard VJ et al. Cognitive status, stroke symptom reports, and modifiable risk factors among individuals with no diagnosis of stroke or transient ischemic attack in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke 2007; 38:1143-7.
25. Vernooij MW, Ikram MA, Tanghe HL et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821-8.
26. Holloway RG, Benesch C, Rush SR: Stroke prevention. Narrowing the evidence-practice gap. Neurology 2000; 54:1899-906.
27. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: Changes over three decades. J Am Coll Cardiol 2003; 42:93-100.
28. Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke - results from a population-based study. Stroke 2005; 36:1115-9.
29. Hart RG, Aearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-67.
30. Petty GW, Brown RDJ, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction - a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50:208-16.
31. Vickrey BG, Rector TS, Wickstrom SL et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33:901-6.
32. Hankey GJ, Jamrozik K, Broadhurst RJ et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000; 31:2080-6.
33. Dhamoon MS, Tai W, Boden-Albala B et al. Risk of myocardial infarction or vascular death after first ischemic stroke: The Northern Manhattan Study. Stroke 2007; 38:1752-8.
34. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-41.
35. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-59.
36. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol, Neurosurg Psychiatry 1996; 60:197-9.
37. Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999; 354:1457-63.
38. ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 367:1665-73.
39. Rothwell PM, Eliasziw M, Gutnikov SA et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361:107-16.
40. Jencks SF, Huff ED, Cuerdon T: Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003; 289:305-12.
41. Scholte op Reimer WJ, Dippel DW, Franke CL et al. Quality of hospital and outpatient care after stroke or transient ischemic attack: Insights from a stroke survey in the Netherlands. Stroke 2006; 37:1844-9.
42. Johnson P, Rosewell M, James MA: How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy? Cerebrovasc Dis 2007; 23:156-61.
43. Brainin M, Teuschl Y, Kalra L: Acute treatment and long-term management of stroke in developing countries. Lancet Neurol 2007; 6:553-61.
44. Hackam DG, Spence JD: Combining multiple approaches for the secondary prevention of vascular events after stroke: A quantitative modeling study. Stroke 2007; 38: 1881-5.
45. Goldstein LB: Gaps in professional and community knowledge about stroke prevention and treatment; in Gorelick PB, Alter M (eds): Stroke Prevention. Boca Raton: Parthenon Publishing, 2002: 149-54.
46. Gemson DH, Elinson J: Vrevention in primary care: variability in physician practice patterns in New York City. Am J Prev Med 1986; 2:226-34.
47. Goldstein LB, Bonito AJ, Matchar DB, Duncan PW, Samsa GP: U.S. national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: Carotid endarterectomy. Stroke 1996; 27:801-6.
48. Goldstein LB, Bonito AJ, Matchar DB et al. U.S. national survey of physician practices for the secondary and tertiary prevention of stroke: design, service availability, and common practices. Stroke 1995; 26:1607-15.
49. Lomas J: Words without action? The production, dissemination, and impact of consensus recommendations. Annu Rev Publ Health 1991; 12:41-65.
50. Greco PJ, Eisenberg JM: Changing physician's practices. N Engl J Med 1993; 329:1271-4.
51. Deplanque D, Leys D, Parnetti L et al. Stroke prevention and atrial fibrillation: Reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57:798-806.
52. Goldstein LB, Cohen SJ, Matchar DB, Bonito AJ, Samsa GP: Physician-reported readiness to change stroke prevention practices. J Stroke Cerebrovasc Dis 1998; 7:358-63.